TCGA-EW-A1P8-01A-11R-A144-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 8
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.560
- MYC_TARGETS_V2+0.540
- MYC_TARGETS_V1+0.460
- G2M_CHECKPOINT+0.430
- ALLOGRAFT_REJECTION+0.400
- MTORC1_SIGNALING+0.330
- IL6_JAK_STAT3_SIGNALING+0.320
- INFLAMMATORY_RESPONSE+0.320
- GLYCOLYSIS+0.300
- UV_RESPONSE_UP+0.280
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.340
- ANDROGEN_RESPONSE-0.230
- UV_RESPONSE_DN-0.230
- FATTY_ACID_METABOLISM-0.220
- PROTEIN_SECRETION-0.220
- BILE_ACID_METABOLISM-0.200
- ESTROGEN_RESPONSE_LATE-0.180
- TGF_BETA_SIGNALING-0.180
- ANGIOGENESIS-0.170
- APOPTOSIS-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0IJ-01A-11R-A034-07 | — | E | 0.869 |
| 2 | TCGA-A2-A0D0-01A-11R-A00Z-07 | — | E | 0.863 |
| 3 | TCGA-AO-A129-01A-21R-A10J-07 | — | E | 0.863 |
| 4 | TCGA-A1-A0SP-01A-11R-A084-07 | — | E | 0.857 |
| 5 | TCGA-A2-A0D2-01A-21R-A034-07 | — | E | 0.852 |
| 6 | TCGA-AR-A1AQ-01A-11R-A12P-07 | — | E | 0.820 |
| 7 | TCGA-D8-A1XK-01A-21R-A14M-07 | — | E | 0.818 |
| 8 | TCGA-BH-A1F6-01A-11R-A13Q-07 | — | E | 0.816 |
| 9 | TCGA-A8-A07O-01A-11R-A00Z-07 | — | E | 0.814 |
| 10 | TCGA-A2-A3XT-01A-11R-A22U-07 | — | E | 0.809 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.280 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| COMPLEMENT | 0.130 | Inavolisib | — uncovered |
| HYPOXIA | 0.130 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.120 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |